First published August 3, 2015 - More info
It is estimated that up to one in five individuals develop pituitary gland tumors. Despite the common occurrence of these tumors, the pathogenetic mechanisms underlying their development remain largely unknown. We report the identification of a novel pituitary tumor–derived, N-terminally truncated isoform of FGF receptor-4 (ptd-FGFR4). The corresponding mRNA results from alternative transcription initiation and encodes a polypeptide that lacks a signal peptide and the first two extracellular Ig-like domains. ptd-FGFR4 has a distinctive cytoplasmic residence, is constitutively phosphorylated, and is transforming in vitro and in vivo. Here we show that targeted expression of ptd-FGFR4, but not FGFR4, results in pituitary tumors that morphologically recapitulate the human disease.
Shereen Ezzat, Lei Zheng, Xian-Feng Zhu, Gillian E. Wu, Sylvia L. Asa
Original citation: J Clin Invest. 2002;109(1):69–78. doi:10.1172/JCI14036.
Citation for this retraction: J Clin Invest. 2015;125(8):3303. doi:10.1172/JCI83399.
An investigation by the University Health Network recently found that portions of the RT-PCR gels shown in Figure 1, B (PGK-1 panel) and C (FGFR1 panel), are duplicated in this publication and in a subsequent publication (1). The samples were labeled differently in the panels, and the marker was shifted in Figure 1B. The corresponding author has indicated that other data from the initial screen of these samples support the conclusions made in the paper; however, the original data for the RT-PCR gels shown in Figure 1 are no longer available. The JCI’s policies prohibit data manipulation and data duplication. Therefore, the JCI is retracting this article. No issues have been raised in regard to any of the other data in this manuscript.
Gillian E. Wu has agreed with the journal’s decision to retract the paper. Sylvia Asa, Shereen Ezzat, and Lei Zheng dissent from the retraction. Coauthor Xian-Feng Zhu could not be reached.